Brown Advisory’s Adial Pharmaceuticals ADIL Stock Holding History

Brown Advisory’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-42	Closed	-$9.11K	–	1181
2023 Q1	$9.11K	Hold	42	–	–	﹤0.01%	1203
2022 Q4	$5.6K	Hold	42	–	–	﹤0.01%	1200
2022 Q3	$9K	Hold	42	–	–	﹤0.01%	1131
2022 Q2	$35K	Hold	42	–	–	﹤0.01%	1089
2022 Q1	$52K	Hold	42	–	–	﹤0.01%	1097
2021 Q4	$70K	Hold	42	–	–	﹤0.01%	1219
2021 Q3	$112K	Hold	42	–	–	﹤0.01%	1080
2021 Q2	$66K	Hold	42	–	–	﹤0.01%	1056
2021 Q1	$63K	Hold	42	–	–	﹤0.01%	1067
2020 Q4	$44K	Hold	42	–	–	﹤0.01%	1008
2020 Q3	$58K	Hold	42	–	–	﹤0.01%	949
2020 Q2	$36K	Hold	42	–	–	﹤0.01%	934
2020 Q1	$34K	Hold	42	–	–	﹤0.01%	923
2019 Q4	$63K	Hold	42	–	–	﹤0.01%	1019
2019 Q3	$39K	Hold	42	–	–	﹤0.01%	995
2019 Q2	$44K	Hold	42	–	–	﹤0.01%	1012
2019 Q1	$89K	Buy	+42	New	+$125K	﹤0.01%	1286

Other funds holding ADIL

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Advisory's ADIL Position: Q2 2023 in Review

Brown Advisory sold out of Adial Pharmaceuticals (ADIL) in Q2 2023, closing a stake of 42 shares — an estimated $9.11K sold.

Brown Advisory first reported a position in ADIL in Q1 2019 and held it in 17 quarters. The position peaked at $112K in Q3 2021. 19 funds tracked by Wall St. Rank hold ADIL as of Q2 2023.

Brown Advisory reported no remaining Adial Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Brown Advisory sold 42 Adial Pharmaceuticals shares in Q2 2023, an estimated $9.11K.
Brown Advisory first reported a position in Adial Pharmaceuticals in Q1 2019 and held it in 17 quarters.
Brown Advisory's Adial Pharmaceuticals position peaked at $112K in Q3 2021.
19 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2023.

Based on Brown Advisory's 13F filing for Q2 2023, filed 31 Jul 2023.